Skip to content
⛰️ FREE SHIPPING ON ORDERS $100 OR MORE ⛰️ Call us Toll-Free: 1-888-687-4334
⛰️ FREE SHIPPING ON ORDERS $100 OR MORE ⛰️ Call us Toll-Free: 1-888-687-4334

Rituxan Hycela (rituximab/hyaluronidase human) 1400mg and 23400 Units Single-Dose Vial **Refrigerated Item**

Save 38%
Original price $ 12,950.95
Current price $ 7,999.95
SKU 50242-0108-01
*** Medical Professional License Required *** License copy must be emailed to sales@mountainside-medical.com. Item ships signature required.
Rituxan hycela is a chemotherapy drug that is used to treat a range of cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. It is a monoclonal antibody, which means that it is designed to target and destroy a specific type of cell. Rituxan hycelA works by binding to the surface of cancer cells and destroying them. This can be a very effective treatment for cancer, but it can also cause some side effects, such as nausea and vomiting.
RITUXAN HYCELA is a combination of rituximab, a CD20-directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, indicated for the treatment of adult patients with:

- Follicular Lymphoma (FL) (1.1)
  • Relapsed or refractory, follicular lymphoma as a single agent Previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single- agent maintenance therapy
  • Non-progressing (including stable disease), follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy
- Diffuse Large B-cell Lymphoma (DLBCL) (1.2)
  • Previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens
- Chronic Lymphocytic Leukemia (CLL) (1.3)
  • Previously untreated and previously treated CLL in combination with fludarabine and cyclophosphamide (FC)

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)